<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141593</url>
  </required_header>
  <id_info>
    <org_study_id>2017VitD3</org_study_id>
    <nct_id>NCT03141593</nct_id>
  </id_info>
  <brief_title>Oral Vitamin D Substitution Weekly or Monthly and Adherence</brief_title>
  <official_title>Oral Vitamin D Substitution Weekly or Monthly - Which Procedure Leads to Highest Adherence? A Prospective Intervention Study in Outpatient Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency (defined as 25(OH)-vitamin D serum level &lt;50 nmol/l) is cured with
      supplementation by mouth. National guidelines recommend the administration of 800 IU
      cholecalciferol daily for an effective treatment, especially during the winter (poor sun
      exposition). Commercially available pharmaceutical forms are liquid in Switzerland (drops)
      and solid forms in Germany (tablets and capsules). Because therapeutic range of vitamin D3 is
      wide and toxicity is seldom reached, even after the consumption of 200'000 IU, and because
      the administration of 8 drops daily is inconvenient, weekly and monthly administrations of
      the cumulative amount (i.e., 5'600 IU weekly or 24'000 IU monthly) have been investigated.
      Both administration schedules are therapeutic equivalent. The study aims to investigate which
      form (liquid or solid) and which schedule (weekly or monthly) procure the highest adherence
      behavior with outpatients under polypharmacy i.e., with 4 or more medications daily. The
      investigators will use commercially available Swiss and German products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention study in patients with serum vitamin D &lt;50 nmol/l and polypharmacy, defined as
      â‰¥4 medicaments/day. Treatment duration: 6 months. Treatment groups are defined as Lm (liquid
      monthly 24'000 IU); Lw (liquid weekly 5'600 IU); Sm (solid monthly 20'000 IU) and Sw (solid
      weekly 5'600 IU). Cross-over design with identical form (liquid or solid) and switching
      frequence, i.e. from weekly to monthly treatment and vice versa, for 3 months each.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patient will be recruited by their GPs and allocated to the GP's form (liquid or solid). Patients will be randomly assigned to start weekly or monthly intake for 3 months, and switch to the other frequence for 3 more months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to medication</measure>
    <time_frame>3 months of treatment</time_frame>
    <description>Taking adherence: number of dosis taken divided by number of dosis prescribed. Timing adherence: number of dosis taken within a time interval (within 15% of the mean preset intake time) divided by number of dosis prescribed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum level of vitamin D</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Level of serum vitamin D compared to baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients preferences</measure>
    <time_frame>3 months of treatment</time_frame>
    <description>Questionnaire with 5-point Likert scale (from 1=strongly disagree to 5=strongly agree)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D: liquid form, start weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D: solid form, start weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D: liquid form, start monthly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D: solid form, start monthly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D: liquid form, start weekly</intervention_name>
    <description>Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.</description>
    <arm_group_label>Vitamin D: liquid form, start weekly</arm_group_label>
    <other_name>Vitamin D3 Streuli</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D: liquid form, start monthly</intervention_name>
    <description>Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.</description>
    <arm_group_label>Vitamin D: liquid form, start monthly</arm_group_label>
    <other_name>Vi-De 3 Monatsdosis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D: solid form, start weekly</intervention_name>
    <description>Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.</description>
    <arm_group_label>Vitamin D: solid form, start weekly</arm_group_label>
    <other_name>Dekristolvit D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D: solid form, start monthly</intervention_name>
    <description>Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.</description>
    <arm_group_label>Vitamin D: solid form, start monthly</arm_group_label>
    <other_name>Dekristol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  vitamin D deficiency by serum level &lt;50 nmol/l

          -  polypharmacy defined as 4 daily medicines or more

          -  speaking German or Swiss German

        Exclusion Criteria:

          -  hypercalcaemia

          -  substitution treatment with cholecalciferol in the past 3 months

          -  medication intake provided by a third person and not by the patient himself
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt E Hersberger, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Rothen, PhD</last_name>
    <phone>+41 61 207 15 67</phone>
    <email>jp.rothen@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Arnet, PhD</last_name>
    <phone>+41 61 207 15 67</phone>
    <email>isabelle.arnet@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pharmaceutical Care Research Group</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Rothen, PhD</last_name>
      <phone>+41 61 207 15 67</phone>
      <email>jp.rothen@unibas.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Isabelle Arnet</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>adherence to medication</keyword>
  <keyword>electronic monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not decided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

